Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 375

1.

Neoadjuvant chemotherapy is associated with improved survival compared with adjuvant chemotherapy in patients with triple-negative breast cancer only after complete pathologic response.

Fisher CS, Ma CX, Gillanders WE, Aft RL, Eberlein TJ, Gao F, Margenthaler JA.

Ann Surg Oncol. 2012 Jan;19(1):253-8. doi: 10.1245/s10434-011-1877-y. Epub 2011 Jul 2.

2.

The role of immunohistochemistry in breast cancer patients treated with neoadjuvant chemotherapy: an old tool with an enduring prognostic value.

Sánchez-Muñoz A, Plata-Fernández YM, Fernández M, Jaén-Morago A, Fernández-Navarro M, de la Torre-Cabrera C, Ramirez-Tortosa C, Lomas-Garrido M, Llácer C, Navarro-Perez V, Alba-Conejo E, Sánchez-Rovira P.

Clin Breast Cancer. 2013 Apr;13(2):146-52. doi: 10.1016/j.clbc.2012.11.006. Epub 2013 Jan 11.

PMID:
23318089
3.

Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer.

Liedtke C, Mazouni C, Hess KR, André F, Tordai A, Mejia JA, Symmans WF, Gonzalez-Angulo AM, Hennessy B, Green M, Cristofanilli M, Hortobagyi GN, Pusztai L.

J Clin Oncol. 2008 Mar 10;26(8):1275-81. doi: 10.1200/JCO.2007.14.4147. Epub 2008 Feb 4.

PMID:
18250347
4.

Neoadjuvant versus adjuvant chemotherapy for triple negative breast cancer.

Kennedy CR, Gao F, Margenthaler JA.

J Surg Res. 2010 Sep;163(1):52-7. doi: 10.1016/j.jss.2010.04.015. Epub 2010 May 6.

PMID:
20599225
5.

Tumor histological subtyping determined by hormone receptors and HER2 status defines different pathological complete response and outcome to dose-dense neoadjuvant chemotherapy in breast cancer patients.

Sánchez-Muñoz A, Plata-Fernández Y, Fernández M, Jaén-Morago A, Fernández-Navarro M, de la Torre-Cabrera C, Ramirez-Tortosa C, Pascual J, Alba E, Sánchez-Rovira P.

Clin Transl Oncol. 2014 Jun;16(6):548-54. doi: 10.1007/s12094-013-1116-z. Epub 2013 Oct 2.

PMID:
24085576
6.

Pathologic complete response after neoadjuvant chemotherapy in HER2-overexpressing breast cancer according to hormonal receptor status.

Tanioka M, Sasaki M, Shimomura A, Fujishima M, Doi M, Matsuura K, Sakuma T, Yoshimura K, Saeki T, Ohara M, Tsurutani J, Watatani M, Takano T, Kawabata H, Mukai H, Naito Y, Hirokaga K, Takao S, Minami H.

Breast. 2014 Aug;23(4):466-72. doi: 10.1016/j.breast.2014.03.008. Epub 2014 Apr 16.

PMID:
24742606
7.

Patient and tumor characteristics associated with breast cancer recurrence after complete pathological response to neoadjuvant chemotherapy.

Ju NR, Jeffe DB, Keune J, Aft R.

Breast Cancer Res Treat. 2013 Jan;137(1):195-201. doi: 10.1007/s10549-012-2312-1. Epub 2012 Nov 13.

8.

Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups.

Untch M, Fasching PA, Konecny GE, Hasmüller S, Lebeau A, Kreienberg R, Camara O, Müller V, du Bois A, Kühn T, Stickeler E, Harbeck N, Höss C, Kahlert S, Beck T, Fett W, Mehta KM, von Minckwitz G, Loibl S.

J Clin Oncol. 2011 Sep 1;29(25):3351-7. doi: 10.1200/JCO.2010.31.4930. Epub 2011 Jul 25.

PMID:
21788566
9.

[Phase II clinical trial of neoadjuvant therapy with carboplatin plus paclitaxel for locally advanced triple-negative breast cancer].

Ma WY, Zhang P, Zhang BL, Wang X, Xu XZ, Zheng S, Wang JY, Cai RG, Yuan P, Ma F, Fan Y, Xu BH.

Zhonghua Zhong Liu Za Zhi. 2012 Oct;34(10):770-4. doi: 10.3760/cma.j.issn.0253-3766.2012.10.011. Chinese.

PMID:
23291072
10.

The Effect of Molecular Subtype and Residual Disease on Locoregional Recurrence in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy and Postmastectomy Radiation.

Yang TJ, Morrow M, Modi S, Zhang Z, Krause K, Siu C, McCormick B, Powell SN, Ho AY.

Ann Surg Oncol. 2015 Dec;22 Suppl 3:S495-501. doi: 10.1245/s10434-015-4697-7. Epub 2015 Jul 1.

11.

Locoregional Control According to Breast Cancer Subtype and Response to Neoadjuvant Chemotherapy in Breast Cancer Patients Undergoing Breast-conserving Therapy.

Swisher SK, Vila J, Tucker SL, Bedrosian I, Shaitelman SF, Litton JK, Smith BD, Caudle AS, Kuerer HM, Mittendorf EA.

Ann Surg Oncol. 2016 Mar;23(3):749-56. doi: 10.1245/s10434-015-4921-5. Epub 2015 Oct 28.

PMID:
26511263
12.

Retrospective analysis of neoadjuvant chemotherapy for breast cancer in Turkish patients.

Duman BB, Afşar ÇU, Günaldi M, Sahin B, Kara IO, Erkisi M, Erçolak V.

Asian Pac J Cancer Prev. 2012;13(8):4119-23.

13.

Adjuvant endocrine therapy in pre- versus postmenopausal patients with steroid hormone receptor-positive breast cancer: results from a large population-based cohort of a cancer registry.

Inwald EC, Koller M, Klinkhammer-Schalke M, Zeman F, Hofstädter F, Lindberg P, Gerstenhauer M, Schüler S, Treeck O, Ortmann O.

J Cancer Res Clin Oncol. 2015 Dec;141(12):2229-40. doi: 10.1007/s00432-015-2025-z. Epub 2015 Aug 8.

14.

Pathologic response to short intensified taxane-free neoadjuvant chemotherapy in patients with highly proliferative operable breast cancer.

Le Tourneau C, Dettwiler S, Beuzeboc P, Alran S, Laurence V, Pierga JY, Fréneaux P, Sigal-Zafrani B, Diéras V, Vincent-Salomon A.

Am J Clin Oncol. 2012 Jun;35(3):242-6. doi: 10.1097/COC.0b013e318209d34c.

PMID:
21358298
15.

MRI staging after neoadjuvant chemotherapy for breast cancer: does tumor biology affect accuracy?

McGuire KP, Toro-Burguete J, Dang H, Young J, Soran A, Zuley M, Bhargava R, Bonaventura M, Johnson R, Ahrendt G.

Ann Surg Oncol. 2011 Oct;18(11):3149-54. doi: 10.1245/s10434-011-1912-z. Epub 2011 Sep 27.

PMID:
21947592
16.

Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.

Kurebayashi J, Kanomata N, Yamashita T, Shimo T, Mizutoh A, Moriya T, Sonoo H.

Breast Cancer. 2015 May;22(3):292-9. doi: 10.1007/s12282-013-0478-y. Epub 2013 Jun 8.

PMID:
23749689
17.

Predictive and prognostic factors in locally advanced breast cancer: effect of intratumoral FOXP3+ Tregs.

Demir L, Yigit S, Ellidokuz H, Erten C, Somali I, Kucukzeybek Y, Alacacioglu A, Cokmert S, Can A, Akyol M, Dirican A, Bayoglu V, Sari AA, Tarhan MO.

Clin Exp Metastasis. 2013 Dec;30(8):1047-62. doi: 10.1007/s10585-013-9602-9. Epub 2013 Jul 9.

PMID:
23836289
18.

Hypervascularity Predicts Complete Pathologic Response to Chemotherapy and Late Outcomes in Breast Cancer.

Bufi E, Belli P, Di Matteo M, Giuliani M, Tumino M, Rinaldi P, Nardone L, Franceschini G, Mulé A, Bonomo L.

Clin Breast Cancer. 2016 Dec;16(6):e193-e201. doi: 10.1016/j.clbc.2016.06.007. Epub 2016 Jun 23.

PMID:
27431459
19.

Magnetic resonance imaging as a predictor of pathologic response in patients treated with neoadjuvant systemic treatment for operable breast cancer. Translational Breast Cancer Research Consortium trial 017.

De Los Santos JF, Cantor A, Amos KD, Forero A, Golshan M, Horton JK, Hudis CA, Hylton NM, McGuire K, Meric-Bernstam F, Meszoely IM, Nanda R, Hwang ES.

Cancer. 2013 May 15;119(10):1776-83. doi: 10.1002/cncr.27995. Epub 2013 Feb 21.

20.

Tumor-infiltrating lymphocytes are correlated with response to neoadjuvant chemotherapy in triple-negative breast cancer.

Ono M, Tsuda H, Shimizu C, Yamamoto S, Shibata T, Yamamoto H, Hirata T, Yonemori K, Ando M, Tamura K, Katsumata N, Kinoshita T, Takiguchi Y, Tanzawa H, Fujiwara Y.

Breast Cancer Res Treat. 2012 Apr;132(3):793-805. doi: 10.1007/s10549-011-1554-7. Epub 2011 May 12.

PMID:
21562709

Supplemental Content

Support Center